
Medical diagnostics co Guardant Health GH.O shares rise 2% to $112.35 premarket
Co reports preliminary Q4 revenue of $280 mln vs analysts' average estimate of $268 mln, according to data compiled by LSEG
Attributes performance to year-on-year surge in oncology testing volumes by 38%
Co also attributes performance to wider adoption of its Smart Liquid Biopsy platform
Volumes for co's blood-based cancer screening test, Shield, increase nearly six times
GH stock more than tripled over past year